Entities / Company
Catalyst Pharmaceuticals.
company in Coral Gables, United States
- Reports this week
- 0
- Active events
- 0
- Connections
- 30
What's happening
Gone quiet
No new reports in 90+ days-
Morgan Stanley began buying shares of Catalyst Pharmaceuticals, which falls under the purview of SEC disclosure requirements.Some support1 report
-
Citigroup downgraded the stock rating and target price for Catalyst Pharmaceuticals on June 16, 2026.Some support1 report
-
Catalyst Pharmaceuticals filed a disclosure with the Securities and Exchange Commission on June 15, 2026.Some support1 report
-
Catalyst Pharmaceuticals, a US biopharma company, is licensed by SERB and previously settled litigation with Teva Pharmaceuticals.Some support2 reports
-
Zacks provided stock analysis and ratings for Catalyst Pharmaceuticals on July 7, 2025.Speculative2 reports
-
Catalyst Pharmaceuticals, SunOpta, and Orion Group were highlighted in a stock analysis report on July 24, 2025.Some support1 report
-
Daniel Curran was appointed to the Board of Directors of Catalyst Pharmaceuticals.Some support1 report
-
Incepta Pharmaceuticals and Catalyst Pharmaceuticals were mentioned in a recent report.Some support1 report
-
Catalyst Pharmaceuticals is based in Coral Gables, Florida.Some support3 reports
-
Lupin and Catalyst Pharmaceuticals settle patent litigation on August 26, 2025, involving FDA approval of Firdapse label expansion for pediatric patients and market generic status.Some support2 reports
-
Richard J. Daly was appointed President and CEO of Catalyst Pharmaceuticals on August 28, 2025.Some support2 reports
No events began in the chosen period. Widen it, or reset.
Around Catalyst Pharmaceuticals this week
News at the entities that move Catalyst Pharmaceuticals most-
FDA StructuralAbbott Laboratories faces an FDA recall classification of its sensors, while Ken Fisher and Donald Trump engage in stock transactions.Moves Catalyst Pharmaceuticals
-
SEC StructuralThe SEC has mandated that filings regarding ETF holdings must be submitted.Moves Catalyst Pharmaceuticals
-
Securities and Exchange Commission StructuralW. R. Berkley Corporation filed its earnings release with the Securities and Exchange Commission on October 1, 2026.Moves Catalyst Pharmaceuticals
-
Morgan Stanley TransactionalMorgan Stanley issued an underweight rating due to relative stock weakness, while favoring Japanese equities.Moves Catalyst Pharmaceuticals
-
Citigroup OperationalCitigroup is divesting from consumer banking in Mexico.Moves Catalyst Pharmaceuticals
-
Coral Gables Shared contextBMI opened its newest office in Coral Gables, Florida, on October 1, 2026, with Jesús González and Leila Cobo attending the ceremony.Moves Catalyst Pharmaceuticals
Connections
The 8 strongest of 30, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Richard J. Daly Structural
Richard J. Daly serves as the President and CEO of Catalyst Pharmaceuticals.
-
FDA Structural
The FDA provides regulatory oversight and approves drug label expansions for Catalyst Pharmaceuticals.
-
SEC Structural
Catalyst Pharmaceuticals operates under the regulatory oversight of the SEC, specifically regarding mandatory disclosure of share holdings.
-
SERB Structural
SERB functions as the licensor for Catalyst Pharmaceuticals, establishing a formal structural dependency.
-
Securities and Exchange Commission Structural
Catalyst Pharmaceuticals operates under the formal regulatory oversight and filing requirements of the SEC.
-
Morgan Stanley Transactional
Morgan Stanley purchased shares of Catalyst Pharmaceuticals.
-
Citigroup Operational
Citigroup downgraded the stock rating and target price for Catalyst Pharmaceuticals.
-
Coral Gables Shared context
Catalyst Pharmaceuticals is based in Coral Gables.
History
Events by the month they beganJuly 2026
1 eventJune 2026
10 events- Citigroup downgraded the stock rating and target price for Catalyst Pharmaceuticals on June 16, 2026.
- Catalyst Pharmaceuticals filed a disclosure with the Securities and Exchange Commission on June 15, 2026.
- Catalyst Pharmaceuticals, a US biopharma company, is licensed by SERB and previously settled litigation with Teva Pharmaceuticals.
- Zacks provided stock analysis and ratings for Catalyst Pharmaceuticals on July 7, 2025.
- Catalyst Pharmaceuticals, SunOpta, and Orion Group were highlighted in a stock analysis report on July 24, 2025.
- Daniel Curran was appointed to the Board of Directors of Catalyst Pharmaceuticals.
- Incepta Pharmaceuticals and Catalyst Pharmaceuticals were mentioned in a recent report.
- Catalyst Pharmaceuticals is based in Coral Gables, Florida.
- Lupin and Catalyst Pharmaceuticals settle patent litigation on August 26, 2025, involving FDA approval of Firdapse label expansion for pediatric patients and market generic status.
- Richard J. Daly was appointed President and CEO of Catalyst Pharmaceuticals on August 28, 2025.